Product Description
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds CLEC12A on myeloid cells and CD3epsilon on cytotoxic T cells. It is being developed by Merus as a novel therapy for acute myeloid leukemia (AML) . (Sourced from: https://pubchem.ncbi.nlm.nih.gov/substance/384403634#section=Available-Date)
Mechanisms of Action: CLL1 Inhibitor, CD3 Binder
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genmab
Company Location: 1253 COPENHAGEN K G7 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03038230 |
MCLA-117-CL01 | P1 |
Terminated |
Acute Myeloid Leukemia |
2021-05-11 |
34% |
2025-04-08 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/14/2020 |
News Article |
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates |
|
06/21/2019 |
News Article |
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market 2019 |